These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 25853301)

  • 1. Albumin: the next-generation delivery technology.
    Howard KA
    Ther Deliv; 2015 Mar; 6(3):265-8. PubMed ID: 25853301
    [No Abstract]   [Full Text] [Related]  

  • 2. Albumin-based drug delivery using cysteine 34 chemical conjugates - important considerations and requirements.
    Caspersen MB; Kuhlmann M; Nicholls K; Saxton MJ; Andersen B; Bunting K; Cameron J; Howard KA
    Ther Deliv; 2017 Jul; 8(7):511-519. PubMed ID: 28555530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Albumin and its application in drug delivery.
    Sleep D
    Expert Opin Drug Deliv; 2015 May; 12(5):793-812. PubMed ID: 25518870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Albumin-based drug delivery: harnessing nature to cure disease.
    Larsen MT; Kuhlmann M; Hvam ML; Howard KA
    Mol Cell Ther; 2016; 4():3. PubMed ID: 26925240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bio-reduction of redox-sensitive albumin conjugates in FcRn-expressing cells.
    Brülisauer L; Valentino G; Morinaga S; Cam K; Thostrup Bukrinski J; Gauthier MA; Leroux JC
    Angew Chem Int Ed Engl; 2014 Aug; 53(32):8392-6. PubMed ID: 24962346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The conserved histidine 166 residue of the human neonatal Fc receptor heavy chain is critical for the pH-dependent binding to albumin.
    Andersen JT; Dee Qian J; Sandlie I
    Eur J Immunol; 2006 Nov; 36(11):3044-51. PubMed ID: 17048273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein.
    Seijsing J; Lindborg M; Höidén-Guthenberg I; Bönisch H; Guneriusson E; Frejd FY; Abrahmsén L; Ekblad C; Löfblom J; Uhlén M; Gräslund T
    Proc Natl Acad Sci U S A; 2014 Dec; 111(48):17110-5. PubMed ID: 25406323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of albumin receptors in regulation of albumin homeostasis: Implications for drug delivery.
    Bern M; Sand KM; Nilsen J; Sandlie I; Andersen JT
    J Control Release; 2015 Aug; 211():144-62. PubMed ID: 26055641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Albumin: a versatile carrier for drug delivery.
    Park K
    J Control Release; 2012 Jan; 157(1):3. PubMed ID: 22119742
    [No Abstract]   [Full Text] [Related]  

  • 10. Impact of albumin on drug delivery--new applications on the horizon.
    Elsadek B; Kratz F
    J Control Release; 2012 Jan; 157(1):4-28. PubMed ID: 21959118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Albumin-based drug designs for pharmacokinetic modulation.
    Pilati D; Howard KA
    Expert Opin Drug Metab Toxicol; 2020 Sep; 16(9):783-795. PubMed ID: 32729729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
    Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
    J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Albumin-Oligonucleotide Assembly for Potential Combinatorial Drug Delivery and Half-Life Extension Applications.
    Kuhlmann M; Hamming JBR; Voldum A; Tsakiridou G; Larsen MT; Schmøkel JS; Sohn E; Bienk K; Schaffert D; Sørensen ES; Wengel J; Dupont DM; Howard KA
    Mol Ther Nucleic Acids; 2017 Dec; 9():284-293. PubMed ID: 29246307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FcRn binding properties of an abnormal truncated analbuminemic albumin variant.
    Andersen JT; Daba MB; Sandlie I
    Clin Biochem; 2010 Mar; 43(4-5):367-72. PubMed ID: 20006594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The New Delivery Strategy of Albumin Carrier Utilizing the Interaction with Albumin Receptors.
    Ishima Y; Maruyama T; Otagiri M; Chuang VTG; Ishida T
    Chem Pharm Bull (Tokyo); 2022; 70(5):330-333. PubMed ID: 35491188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A strategy for bacterial production of a soluble functional human neonatal Fc receptor.
    Andersen JT; Justesen S; Berntzen G; Michaelsen TE; Lauvrak V; Fleckenstein B; Buus S; Sandlie I
    J Immunol Methods; 2008 Feb; 331(1-2):39-49. PubMed ID: 18155020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Human serum albumin: gene-technological possibilities].
    Kragh-Hansen U
    Ugeskr Laeger; 2008 Sep; 170(38):2958-62. PubMed ID: 18808748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deciphering albumin-directed drug delivery by imaging.
    Hu H; Quintana J; Weissleder R; Parangi S; Miller M
    Adv Drug Deliv Rev; 2022 Jun; 185():114237. PubMed ID: 35364124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of delivery of omega-3 fatty acids to human cancer cells by low-density lipoproteins versus albumin.
    Edwards IJ; Berquin IM; Sun H; O'flaherty JT; Daniel LW; Thomas MJ; Rudel LL; Wykle RL; Chen YQ
    Clin Cancer Res; 2004 Dec; 10(24):8275-83. PubMed ID: 15623603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracellular delivery of cytochrome c by galactosylated albumin to hepatocarcinoma cells.
    Yeh TH; Wu FL; Shen LJ
    J Drug Target; 2014 Jul; 22(6):528-35. PubMed ID: 24731058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.